title: [What's new in oncology?].
abstract: In cutaneous oncology, the year 2012 was marked by the consolidation of earlier results as well as the emergence of new therapeutic perspectives. The consolidated results most notably concern the use of MAP-kinase inhibitors (anti-MEK, anti-BRAF) in the treatment of patients with metastatic melanoma. Vismodegib (an SMO inhibitor), used in the treatment of multiple basocellular carcinomas that are inoperable or that have developed in patients suffering from Gorlin syndrome, has been the subject of publication of large-scale studies. Of the new therapeutic advances, let us mention the use of inhibitors or monoclonal antibodies directed against the PD1 receptor and its ligand PD-L1, the combination of MEK and BRAF inhibitors in the treatment of metastatic melanoma, and treatment in adjuvant situations with these same inhibitors. Beyond these significant advances that must be credited to cutaneous oncology, new questions are emerging relative to the side effects observed with these targeted therapies. The onset of multiple epidermoid carcinomas or primary melanomas treated with BRAF inhibitors is a striking illustration of the paradoxes arising from the clinical transfer of scientific progress. The intellectual perspectives are therefore numerous. It is hoped that this work will succeed in making these innovative drugs available to the patients who will have contributed to their development through their participation in clinical trials.
authors.affiliation: Service de Dermatologie, Centre Hospitalier Lyon Sud, 165, chemin du Grand Revoyet, 69495 Pierre Bénite cedex 08, France. stephane.dalle@chu-lyon.fr
authors.forename: S
authors.initials: S
authors.lastname: Dalle
mesh_terms: D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000473:pathology*; D003880:Dermatology / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary*; D048308:Mitogen-Activated Protein Kinase 14 / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D048308:Mitogen-Activated Protein Kinase 14